breast cancer and glp 1 Is GLP-1 Safe for Survivors? Evidence Guidance – Bolt Pharmacy GLP-1s in Oncology: Nursing Insights

92 SatoT.YamochiT.YamochiT.AytacU.OhnumaK.McKeeK

Key Takeaway: The SELECT trial cardiovascular indication for Wegovy and the SURMOUNT-OSA indication for Zepbound create separate coverage pathways What If Aetna Denies Coverage

A systematic review and meta-analysis published in eClinicalMedicine found that discontinuing GLP-1 receptor agonist treatment led to an average weight regain of 5.63 kg and 5.81% of body weight across all patients studied

Part of our responsibility to the millions of customers who trust us with their healthcare is to understand the scale of the challenges they face and use our platform to combat them. Branded GLP-1 medications are challenging to access across the country, with availability fluctuating up and down as drugmakers invest in their ability to meet the immense amount of demand